Evans John M.'s Form 4 filing
Beam Therapeutics Inc. (BEAM) · filed Feb 2, 2024
- Accession no.
- 0000950170-24-010477
- Filed
- Feb 2, 2024
- Trade date
- Jan 31, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $1.52M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Evans John M.CIK 0001786304 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Common Stock | SSaleDisposed | −60,000 | $25.33 | −$1,519,800 | 1,058,262 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Common Stock | AGrant or awardAcquired | +155,000 | $24.40 | +$3,782,000 | 155,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.